H.B. Fuller reported strong Q3 2026 results with revenue up 5.2% to $938 million and adjusted EBITDA rising 9%. The record EBITDA margin was driven primarily by effective pricing strategies in a compe
H.B. Fuller refinanced $420 million in term loans and extended maturities despite a recent share price decline. Analysts estimate the stock is 23% undervalued at $73.29, although rising raw material c
H.B. Fuller secured new Term A loans and expanded its revolving credit facility to $800 million while declaring a $0.245 quarterly dividend. Despite improved liquidity, high net debt to EBITDA remains
H.B. Fuller refinanced its credit agreement to extend maturities and secure lower interest margins, yet shares trade significantly below fair value estimates. Analysts highlight revenue growth potenti
H. B. Fuller (FUL) is highlighted as an attractive value investment with favorable valuation metrics compared to industry averages, suggesting potential undervaluation.
H.B. Fuller focuses on margin improvement through portfolio optimization and medical expansion rather than volume growth. Despite strong recent financial results, demand friction remains while the com
H.B. Fuller leverages specialty materials positioning to expand into medical markets while countering inflation through pricing strategies. Despite strong valuation, sustained volume growth remains ch
ChemBrief